FilingsTodayOscar Health
At a glance
Oscar Health reported 2025 revenue of $28.6M, up 39% from $20.6M in 2024. Over 4 years since 2021 ($5.4M), that is growth of about 51.7% a year. Operating margin was -1386.2%, up from -10094.2% in 2021. Revenue peaked in 2022 at $64.9M. The company posted a loss in 2021, 2022, 2023 and 2025.
In the last 12 months 7 insiders reported 1 open-market purchase ($11.9M) and 34 sales ($150M). 31 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $35.8M by Chief Executive Officer Mark T Bertolini on Jul 1, 2026. Net, insiders were sellers of $138.1M.
Oscar Health filed 11 current reports (Form 8-K) in the last 12 months, most often for regulation fd disclosure (4), results of operations (4), officer or director change (2) and shareholder vote results (1). The latest officer or director change was reported on Jun 2, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
2 of the 20 investors tracked here held Oscar Health at the last quarter end, worth $99.8M combined. It is the largest weight for Renaissance Technologies (0.1% of its portfolio), followed by Bridgewater Associates (0%). New this quarter: Renaissance Technologies and Bridgewater Associates.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$572.6M | -$606.3M | -$270.7M | $25.4M | -$443.2M |
| Diluted EPS | $-3.20 | $-2.85 | $-1.22 | $0.10 | $-1.69 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined